ko	pathway	ratio_in_study	ratio_in_pop	p_value
ko03050	Proteasome	4/25	54/7206	3.17091382551e-05
ko04115	p53 signaling pathway	3/25	74/7206	0.00203287288802
ko03008	Ribosome biogenesis in eukaryotes	3/25	79/7206	0.00245173083897
ko05210	Colorectal cancer	3/25	86/7206	0.00312256405953
ko05216	Thyroid cancer	2/25	34/7206	0.00605689655431
ko05020	Prion diseases	2/25	40/7206	0.0083149884968
ko01522	Endocrine resistance	3/25	124/7206	0.00867647474829
ko00970	Aminoacyl-tRNA biosynthesis	2/25	44/7206	0.0099995668184
ko05219	Bladder cancer	2/25	48/7206	0.0118229185269
ko04110	Cell cycle	3/25	145/7206	0.0132723659342
ko05213	Endometrial cancer	2/25	62/7206	0.0192427344465
ko05161	Hepatitis B	3/25	173/7206	0.0212224579964
ko05223	Non-small cell lung cancer	2/25	66/7206	0.0216441096623
ko04210	Apoptosis	3/25	180/7206	0.0235431406117
ko05014	Amyotrophic lateral sclerosis (ALS)	2/25	74/7206	0.026799039547
ko05167	Kaposi's sarcoma-associated herpesvirus infection	3/25	191/7206	0.0274613456804
ko01524	Platinum drug resistance	2/25	76/7206	0.0281586422046
ko04612	Antigen processing and presentation	2/25	77/7206	0.0288487846642
ko05214	Glioma	2/25	79/7206	0.0302494928814
ko05212	Pancreatic cancer	2/25	83/7206	0.0331311680929
ko05220	Chronic myeloid leukemia	2/25	85/7206	0.0346113243564
ko05218	Melanoma	2/25	85/7206	0.0346113243564
ko05222	Small cell lung cancer	2/25	89/7206	0.0376482768481
ko03015	mRNA surveillance pathway	2/25	93/7206	0.040784798089